Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 8/20 | 0.57 |
| ▸ | FGF1 | P05230 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | PYGB | P11216 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151561 | 1.00 | LGALS8 (0.57) | LGALS8FGF1OGAL3MBTL1GAA | |
| SCHEMBL10781121 | 1.00 | LGALS8 (0.57) | LGALS8FGF1OGAL3MBTL1GAA | |
| SCHEMBL25505097 | 1.00 | LGALS8 (0.57) | LGALS8FGF1OGAL3MBTL1GAA | |
| SCHEMBL13180919 | 1.00 | LGALS8 (0.57) | LGALS8FGF1OGAL3MBTL1GAA | |
| SCHEMBL14010636 | 1.00 | LGALS8 (0.57) | LGALS8FGF1OGAL3MBTL1GAA | |
| SCHEMBL10781125 | 1.00 | LGALS8 (0.57) | LGALS8FGF1OGAL3MBTL1GAA | |
| SCHEMBL23705114 | 0.94 | LGALS8 (0.51) | LGALS8FGF1L3MBTL1GAAMAPT | |
| SCHEMBL7147710 | 0.94 | LGALS8 (0.51) | LGALS8FGF1L3MBTL1GAAMAPT | |
| SCHEMBL14846432 | 0.94 | LGALS8 (0.55) | LGALS8FGF1OGAL3MBTL1GAA | |
| SCHEMBL20115303 | 0.94 | LGALS8 (0.55) | LGALS8FGF1OGAL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253584-A1 | PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | GILEAD PHARMASSET LLC (US) | 2017-09-07 | — | — | US | disclosed |
| US-8481713-B2 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives | GILEAD PHARMASSET LLC (US) | 2013-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253584-A1 | PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | NSUN2, FBL, RNGTT | LGALS8 2048/4885FGF1 3407/4885OGA 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.